Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Dividend Re-investment (2009 Performance Share Plan) |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Date | July 14, 2016 |
| Share Price | £16.285 |
| Total Volume Acquired | 2,674.212 shares |
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Mr. D S Redfern, Chief Strategy Officer. This change resulted from the automatic re-investment of dividends paid on July 14, 2016, into the Company's 2009 Performance Share Plan. No material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of a specific executive shareholding change.
Key Facts for Investor Verification
- The transaction involves Mr. D S Redfern, Chief Strategy Officer, increasing his shareholding via dividend re-investment.
- The transaction occurred on July 14, 2016, at a price of £16.285 per share.
- A total of 2,674.212 shares were acquired across three separate entries.
- This filing does not contain financial performance data for GSK Plc.